Brief: FDA Provides Positive Feedback To Vistagen Regarding Use Of The Liebowitz Social Anxiety Scale (Lsas) As An Endpoint In Phase 3 Development Of Fasedienol (Ph94b) For Treatment Of Social Anxiety Disorder

Vistagen Therapeutics

30/03/2023 14:51

March 30 (Reuters) - VistaGen Therapeutics Inc  VTGN.O :
    * FDA PROVIDES POSITIVE FEEDBACK TO VISTAGEN REGARDING USE
OF THE
LIEBOWITZ SOCIAL ANXIETY SCALE (LSAS) AS AN ENDPOINT IN PHASE 3
DEVELOPMENT OF FASEDIENOL (PH94B) FOR TREATMENT OF SOCIAL
ANXIETY DISORDER
    * VISTAGEN THERAPEUTICS INC - PLANS TO USE LSAS AS PRIMARY
EFFICACY ENDPOINT FOR A PHASE 3 CLINICAL STUDY
    * VISTAGEN THERAPEUTICS INC: FDA FEEDBACK CONFIRMING
ACCEPTABLE
USE OF LSAS AS A PRIMARY EFFICACY ENDPOINT

Source text for Eikon:  ID:nBw55yvkxa 
Further company coverage:  VTGN.O 

 ((reuters.briefs@thomsonreuters.com;))